AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05389904 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Arm 2: Preemptive C. difficile infection prevention bundle
Description: Patients colonized with toxigenic C. difficile, identified by testing routinely collected swabs for vancomycin-resistant enterococcus screening, will receive a preemptive prevention bundle for C. difficile. The prevention bundle will include enhanced room cleaning, C. difficile precautions (staff entering room must wear gown and gloves and wash hands with soap and water upon exiting the room), pharmacist review and optimization of antibiotics and antacids, and consideration of vancomycin prophylaxis.
Study NCT04276714 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Socket without Revofit system
Description: All the tests are evaluate during one week with the classical type of fittings
Study NCT04276714 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Socket with Revofit system
Description: All the tests are evaluate during one week with the adjustable type of fittings (that is to say with Revofit system)
Study NCT06045260 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-DOTATOC
Description: Administration of 4 cycles of therapy with 7.4 Gbq Dose for No risk factors Arm and 5.5 Gbq Dose for Risk Factor Arm. Both through slow intravenous infusion in 30 minutes with a dedicated pump system.
Study NCT06195423 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stop OsteoARthritis (SOAR) program
Description: The SOAR program is a 6-month, online-delivered (videoconferencing), PT-guided knee health program which consists of;~1. Knee Camp: Includes interactive education, and 1:1 physiotherapy knee exam and counseling session to co-identify home-based exercise-therapy and physical activity goals to address participants' unique functional limitations. Participants are given a wrist-worn activity monitor to wear 24hours/day.~2. Individualized Weekly Home-based Exercise-Therapy and Physical Activity Program: At home, participants work to meet their exercise-therapy and physical activity goals. Exercises and physical activity are tracked with an online form and the activity monitor. Participants can also attend an optional weekly group class.~3. Weekly PT-guided Exercise-Therapy and Physical Activity Counselling: Each week, participants attend a 1:1 physiotherapist counseling session to modify exercise-therapy and physical activity goals.
Study NCT06195423 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Living Well after ACLR program
Description: Participants in the minimal intervention CONTROL group will receive access to a 30-minute educational video (knee anatomy, ACLR information, general exercise, physical activity, and goal-setting principles), a best practice workbook, one video-recorded virtual session with a physiotherapist (naïve to SOAR) who will explain the booklet and answer questions but not volunteer information beyond the video or booklet and the same wrist-worn activity tracker as the experimental group.
Study NCT04686331 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Biomarkers for pneumonia
Description: Blood samples will be collected by a medical laboratory technologist and transferred to the local laboratory for analysis of surfactant protein D, Krebs von den Lungen (KL-6), and YKL-40. Laboratory staff will be blinded to participant diagnosis and outcome. None of the biomarkers will be available to the treating physician.~* Diagnostic test of surfactant protein D - will be quantified using enzyme-linked immunosorbent assay (ELISA)-based analysis~* Diagnostic test of KL-6: will be quantified using enzyme-linked immunosorbent assay (ELISA)-based analysis~* Diagnostic test of YKL-40 - will be quantified using enzyme-linked immunosorbent assay (ELISA)-based analysis
Study NCT05773378 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pessary Intervention
Description: Participants will receive a 3-size fitting kit and will fit the appropriate size based on manufacturer instruction. Once the size is verified, the participants will be asked to use the pessary while running over a 10-week period.
Study NCT05773378 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tampon Intervention
Description: Participants will receive 60 regular Tampax tampons and will be instructed to use them each time they run over a 10-week period.
Study NCT05517590 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic acid
Description: 1 gram of tranexamic acid will be diluted into 100 ml of saline solution and administered at a rate of 100 ml/hr 10 minutes before the skin incision time.
Study NCT05517590 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 100 ml of saline solution will be administered at a rate of 100 ml/hr 10 minutes before the skin incision time.
Study NCT03903224 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Combined Modified Pectoralis and Transversus Plane Blocks
Description: Modified pectoralis nerve block (Pecs II) aims to block at least the pectoral nerves, the intercostobrachial, intercostals III-IV-V-VI. This will cover dermatomes T2, T3 and T4. The probe is positioned under the lateral third of the clavicle .After locating the subclavian muscle, the axillary artery and the axillary vein we move the probe distally towards the axilla, until the pectoralis minor is identified. We start counting the ribs , from r1 under the axillary artery, we move distally and laterally until the lateral border of pectoralis minor is reached. The serratus anterior muscle which covers r2, r3, r4 is the point of entrance into the axilla.~Blocking of multiple anterior branches of intercostal nerves (Th2-6) using a transversus thoracic muscle plane (TTP) block is used as an additive to pecs II to cover the internal mammary region
Study NCT03903224 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector Spinae block
Description: The patient is placed in a sitting position and The T5 spinous process is located by palpating and counting down from the C7 spinous process. Under complete aseptic conditions a linear ultrasound probe is then placed in a transverse orientation at the level of the T5 transverse process. The tip of the transverse process is centred on the ultrasound screen and the probe is then rotated into a longitudinal orientation to produce a parasagittal view. From T1 to T5 the erector spinae, rhomboid major and trapezius muscles are visible posterior and superficial to the transverse processes.
Study NCT06254729 — intervention group
Intervention type: OTHER
Intervention: Observational study
Description: Our study does not have any exposure factors.
Study NCT04454190 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Collection of genetic material
Description: Blood samples will be processed for extraction of DNA and genotyping. 10 ml of blood will be collected using standard procedures. The samples will be de-identified and receive a masked ID which will correspond to the existing masked ID in the DGR database. 2 ml will be sent to Genentech using frozen samples for genotyping using the Illumina Global Screening Array (GSA) kit. The remaining will be processed and stored at the Duke Eye Center. These samples may be maintained indefinitely or until they are exhausted. These samples will not be available for diagnostic or therapeutic purposes.
Study NCT05658315 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ApplTree smartphone application
Description: ApplTree is a smartphone reminder application which allows the user to enter details of future tasks and events and then prompts the user to remind them to complete these at a pre-specified time. ApplTree was designed with people who experience memory and attention difficulties in mind and has a customisable user interface design to support attention and short-term memory when entering PM tasks. ApplTree was developed by Professor Jonathan Evans and Dr Matthew Jamieson (see Jamieson et al., 2020) and is owned by the University of Glasgow.
Study NCT04424602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclo phosphamide
Description: 500mg vial
Study NCT04424602 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mycophenolate
Description: 500mg film-coated tablets.
Study NCT05684107 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: IPACK block
Description: the probe is applied to the popliteal fossa for identification of the popliteal artery and femur. Then, the probe is slid distally for revealing the two femoral condyles followed by proximal sliding of the probe until the humps of the femoral condyles disappeared and the flat metaphysis appeared. a spinal needle 22G x 3.5 inches is advanced from the lateral aspect and directed across the space between the popliteal artery and femur and once the needle reached the medial edge of the femur, nearly at the level of the popliteal artery, negative aspiration is confirmed and 20 ml of bupivacaine 0.25% is injected incrementally as the needle was withdrawn
Study NCT05684107 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: adductor canal block
Description: the transducer is placed anteromedially, approximately at the junction between the middle and distal third of the thigh or somewhat lower.~The saphenous nerve block should be performed at the most distal level where the artery still lies immediately deep to the sartorius muscle, thus minimizing the amount of motor nerve block of the vastus medialis; an adductor canal nerve block is typically performed more proximally, around the mid-thigh level. The needle is inserted in-plane in a lateral-to-medial orientation and advanced toward the femoral artery. Once the needle tip is visualized anterior to the artery and after careful aspiration, 20 ml of bupivacaine 0.25% is injected incrementally as the needle was withdrawn
Study NCT05684107 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: sciatic nerve block
Description: patient in a supine position with the hip and knee on the operated side flexed and the leg externally rotated at approximately 45 degrees. The ultrasound transducer is first positioned perpendicular to the skin approximately 8 cm distal to the inguinal crease. The location is then scanned by sliding and tilting the transducer until a clear transverse image of the hyperechoic sciatic nerve located posterior and medial to the lesser trochanter is obtained. a spinal needle 22G x 3.5 inches is advanced parallel and in line with the ultrasound transducer while the sciatic nerve is kept in the middle of the screen. The needle is advanced slowly under real-time ultrasound guidance until it is near the nerve then negative aspiration is confirmed and 20 ml of bupivacaine 0.25% is injected incrementally as the needle was withdrawn
Study NCT02124226 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: 7.5 mg/week + folic acid the day after
Study NCT02124226 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matched placebo
Study NCT04659213 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: esolution catheter
Description: esolution is a catheter-based therapy designed to displace the esophagus away from the source of ablation energy during ablation of AF and to eliminate the risk of esophageal injury
Study NCT06316024 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: water
Description: The participants drink 240 mL of water approximately 6-8 hours after surgery
Study NCT06316024 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: juice/sport drink group
Description: The participants drink 240 mL of juice/sport drink approximately 6-8 hours after surgery
Study NCT06316024 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Chewing gum group
Description: The participants eat chewing gum approximately 6-8 hours after surgery
Study NCT06382376 — intervention group
Intervention type: PROCEDURE
Intervention: Intrathecal morphine administered group, Four quadrant transversus abdominis plane block applied group
Description: Intrathecal morphine administered group and Four quadrant transversus abdominis plane block applied group
Study NCT05213767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB2916 injection
Description: TQB2916 injection is a kind of Tumor necrosis factor receptor superfamily member 5 (CD40) agonist, which is a humanized immunoglobulinG2 (IgG2) monoclonal antibody targeting CD40. This product can bind to CD40 on target cells to activate downstream signaling pathways and generate anti-tumor immune responses. At the same time, it can promote the apoptosis of B-cell lymphoma Ramos cells.
Study NCT06282133 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioural Experiments for Intolerance of Uncertainty
Description: Behavioural experiments involve selecting a specific thought to test (for example, uncertainty makes me incapable of acting) and designing a detailed experiment to challenge this thought.
Study NCT04710472 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mentora App
Description: Participants will be invited to register their treatment side effects, symptoms, daily activities and exercise and QoL on a health app designed for this purpose.~The Mentora Health App includes a tool based on PRO-CTCAE™, a patient-reported outcome measurement system developed by the National Cancer Institute, version 1.1, that includes 80 symptoms (attachment 1) and has been translated and validated to Portuguese (Portugal) by the authoring entity. These symptoms are graded on a five-point scale from 0 (not present) to 4 (disabling) based on clinical criteria.
Study NCT06132815 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser troughing
Description: Laser troughing will be carried out by passing laser optic fiber in contact mode along the gingival sulcus. Laser energy will be delivered with a wavelength of 980nm and power of 0.8W, in continuous mode. Laser tip will be inserted 1mm into the gingival sulcus, to facilitate an accurate recording of finish line
Study NCT06132815 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Retraction cord and astringent
Description: Partial isolation of the tooth with cotton rolls and saliva ejector will be performed. Appropriate size of retraction cord will be soaked in astringent for 5 mins. Then packing of the cord will be started from the mesial interproximal area by gently packing into the sulcus with the gingival cord packer instrument using the single cord technique. Retraction cord will be kept in place for 5 minutes. Cord will be removed immediately before the start of the intraoral scan
Study NCT06132815 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cordless retraction paste with astringent
Description: The cordless paste with astringent will be injected gently into the sulcus, leaning on the tooth at the point of the cervical limit and not on the gingiva, the cannula will remain parallel to the axis of the tooth to exert optimal pressure. Then it will removed after 5 mins with copiously irrigated water until no traces of the materials left.
Study NCT06132815 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cordless retraction paste without astringent
Description: The cordless paste without astringent 10 will be injected into the sulcus of the gingiva. The suitable size of Comprecap will be held on the abutment to push the material deep into the sulcus of the gingiva, and the participants will be informed to bite over it for a period of 3 to 5 minutes. After 5 minutes, the comprecap with the set retraction material attached to it, will be removed from the patient mouth.
Study NCT05966688 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPR720
Description: Multiple oral doses of SPR720 capsules.
Study NCT05966688 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: Multiple oral doses of azithromycin.
Study NCT05966688 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethambutol
Description: Multiple oral doses of ethambutol.
Study NCT05063773 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mixed reality heads up display
Description: Physician will use a mixed reality headset for image guidance of the procedure
Study NCT05928195 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Acute Moderate-Dose Guayusa Extract Supplementation
Description: Participants will consume two vegan capsules with one capsule containing 600 mg AmaTea® and 1 containing 600 mg dextrose.
Study NCT05928195 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Acute High-Dose Guayusa Extract Supplementation
Description: Participants will consume two vegan capsules with each capsule containing 600 mg AmaTea® (1200 mg total).
Study NCT05928195 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will consume two vegan capsules with each capsule containing 600 mg dextrose (1200 mg total).
Study NCT05603234 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Symptom Monitoring
Description: Reporting symptoms each day via a symptom questionnaire
Study NCT06373809 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Transplantation of Placenta Derived Stem Cells
Description: Subcutaneously administered placental-derived SVF / PDSC cells in foot, ankle, and calf tissues in 20 DFU patients
Study NCT05468632 — intervention group
Intervention type: DRUG
Intervention: Semaglutide
Description: Participants who initiated once weekly (OW) semaglutide in routine clinical practice in were enrolled in the study. The participants were treated according to current clinical practice, applicable local labels, and standard of care as per physicians' discretion.
Study NCT05761028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CM310
Description: CM310 Recombinant Humanized Monoclonal Antibody Injection
Study NCT05761028 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT05846685 — intervention group
Intervention type: OTHER
Intervention: Patient Phone Interviews
Description: Collecting perceptions about automated falls-risk screening and referral tool
Study NCT05846685 — intervention group
Intervention type: OTHER
Intervention: Patient In Person Interviews
Description: Interviews will be aimed at collecting patient input necessary to adapt the design of the intervention at these sites.
Study NCT06252064 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation + Drug therapy
Description: Patients in the Combo group underwent rehabilitation treatment combined with drug therapy: the rehabilitation protocol included daily sessions, 5 days a week, lasting 60 minutes, for a total of 4 consecutive weeks. Patients included in this group also took drug therapy, particularly Pridinol Mesylate orally, on an empty stomach, 2 mg x 3 times a day for 20 days.
Study NCT06252064 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation
Description: Patients in the Reha group underwent rehabilitation treatment: the rehabilitation protocol included daily sessions, 5 days a week, lasting 60 minutes, for a total of 4 consecutive weeks. The treatment included an initial step, lasting 40 minutes, of Postural Reeducation ending with Stretching exercises of the posterior kinetic chain muscles lasting 20 minutes.
Study NCT06252064 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Drug therapy
Description: The Drug Group had taken Pridinol Mesylate orally, on an empty stomach, 2 mg x 3 times a day for 20 days. The tablet was taken without chewing and with a glass of water (200 ml). The drug was taken in environments with temperature below 25° C.
Study NCT04799886 — intervention group
Intervention type: OTHER
Intervention: Semi structured interview
Description: Interviews are performed by one research group member and based on beforehand decided questions and sub-questions. The interview material is transcribed and analysed on a theme level.
Study NCT06471400 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: interview
Description: patient relatives or legal authorized representatives will be interviewed
Study NCT04793022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TIVA with Propofol
Description: Total intravenous anesthesia with propofol
Study NCT04793022 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inhaled Anesthesia
Description: General anesthesia given with inhaled anesthetics
Study NCT05025956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fisetin
Description: Oral Fisetin 20 mg/kg taken for 8 days total.
Study NCT05025956 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Fisetin appearance-matched microcrystalline cellulose placebo. 20 mg/kg taken for 8 days total.
Study NCT04639180 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: Subjects receive Camrelizumab intravenously, Dosage form: lyophilized powder
Study NCT04639180 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivoceranib (Apatinib)
Description: Subjects receive Rivoceranib (Apatinib) orally, Dosage form: tablet
Study NCT05458076 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QLS1128 A-Dose 1~5 and Ritonavir
Description: Cohort 1:~QLS1128 A-Dose 1 or Placebo~Cohort 2:~Period 1: QLS1128 A-Dose 2 or Placebo, on day 1. Period 2:QLS1128 A-Dose 2 or Placebo with high fat meal on day 5. Period 3:QLS1128 A-Dose 2 or Placebo plus Ritonavir on day 9~Cohort 3:~QLS1128 A-Dose 3 or Placebo~Cohort 4:~QLS1128 A-Dose 4 or Placebo~Cohort 5:~QLS1128 A-Dose 5 or Placebo
Study NCT05458076 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QLS1128 C-Dose 1~3 and Ritonavir
Description: Cohort 6:~Period 1: QLS1128 C-Dose 1 or Placebo, twice daily for 7 days. Period 2:QLS1128 C-Dose 1 or Placebo plus Ritonavir , twice daily for 7 days~Cohort 7:~Period 1: QLS1128 C-Dose 2 or Placebo, twice daily for 7 days. Period 2:QLS1128 C-Dose 2 or Placebo plus Ritonavir , twice daily for 7 days~Cohort 8:~Period 1: QLS1128 C-Dose 3 or Placebo, twice daily for 7 days. Period 2:QLS1128 C-Dose 3 or Placebo plus Ritonavir , twice daily for 7 days